Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals

Completed

• Conditions: Hypertension
• Interventions: Drug: Telmisartan

• Registration Number: NCT02238262
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

The aim of the observational study was to supplement the data on efficacy, safety and tolerability of telmisartan under daily conditions in hospitals

Detailed Description

Not available

Study Timeline

• Study Start: 2000-05
• Primary Completion: 2000-12
• Status Verified: 2014-09
• Study First Submitted: 2014-09-11
• Study First Submitted QC: 2014-09-11
• Last Update Submitted: 2014-09-11
• Study First Posted: 2014-09-12
• Last Update Posted: 2014-09-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2318

Inclusion Criteria

• Patients with diagnosis of essential hypertension
• Minimum age of 18 years

Exclusion Criteria

• NA

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
essential hypertension patients	Telmisartan	-

Primary Outcome Measures

Name	Time	Method
Change in clinic blood pressure	up to 14 days
Number of patients with adverse drug reactions	up to 14 days